CMV retinitis study aborted

GMHC Treat Issues. 1996 Sep;10(9):8.


AIDS: A study of the experimental anti-cytomegalovirus (CMV) drug, MSL-109 manufactured by Protein Design Labs, was halted after an interim analysis found that the treatment offered no benefit over placebo, and that more deaths appeared to occur among patients receiving the drug. Two other large MSL-109 studies are still ongoing. One study, a CMV prophylaxis study in bone marrow transplant patients, is continuing due to lack of abnormal mortality or side effects being reported. Another study conducted by ACTG, study #266, has been placed on temporary hold.

Publication types

  • Clinical Trial
  • Newspaper Article
  • Randomized Controlled Trial

MeSH terms

  • Antiviral Agents / adverse effects
  • Antiviral Agents / therapeutic use*
  • Bone Marrow Transplantation / adverse effects
  • Cytomegalovirus Infections / prevention & control
  • Cytomegalovirus Retinitis / drug therapy*
  • Humans
  • Placebos
  • Randomized Controlled Trials as Topic
  • Treatment Failure


  • Antiviral Agents
  • Placebos